Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a.
Allergen-specific immunotherapy is the only treatment that can alter the natural course of allergic disease. We performed long-term sublingual immunotherapy (SLIT) for patients with seasonal allergic rhinitis caused by Japanese cedar pollen (SAR-JCP), screened molecules as candidate biomarkers, and investigated serum IL-17A and complement components 3a (C3a) and C5a in order to evaluate whether these molecules show changes correlated to symptom scores. In this study, we found that the long-term SLIT reduced the serum levels of IL-17A and C3a and C5a. The levels of C3a in the patients significantly decreased from year 1 compared with those at the baseline, and their levels of IL-17A significantly decreased from year 2 compared with those at baseline. The levels of IL-17A, C3a, and C5a at year 4 of SLIT were significantly lower than not only those at baseline, but also those at year 1. A significant positive correlation was found between the symptom medication scores and the levels of IL-17A at year 4. The symptom medication scores in the group in which IL-17A levels decreased at year 4 were significantly lower than those in the group without such a decrease. The serum level of IL-17A might prove useful as a biological parameter to ascertain the effectiveness of SLIT for patients with SAR-JCP. It is necessary to produce new therapeutics for non-responders in whom serum IL-17A levels are still higher against long-term SLIT.
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Masafumi
M
Sakashita
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan. Electronic address: ymdtkcy@gmail.com.
Takechiyo
T
Yamada
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Yoshimasa
Y
Imoto
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan; Laboratory for Respiratory and Allergic Diseases, Center for Genomic Medicine, RIKEN, Yokohama, Japan.
Tomomitsu
T
Hirota
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan; Laboratory for Respiratory and Allergic Diseases, Center for Genomic Medicine, RIKEN, Yokohama, Japan.
Mayumi
M
Tamari
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Yumi
Y
Ito
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Seita
S
Kubo
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Yoko
Y
Osawa
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Noboru
N
Takahashi
Department of Otorhinolaryngology, University of Fukui, Fukui 910-1193, Japan.
Shigeharu
S
Fujieda
D000286:Administration, Sublingual; D000328:Adult; D000368:Aged; D000485:Allergens / Q000276:immunology; D000706:Anaphylatoxins; D015926:Complement C3a / Q000276:immunology*; D015936:Complement C5a / Q000276:immunology*; D032485:Cryptomeria; D003888:Desensitization, Immunologic / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007167:Immunotherapy; D020381:Interleukin-17 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011058:Pollen / Q000276:immunology*; D065631:Rhinitis, Allergic / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D063729:Sublingual Immunotherapy; D013997:Time Factors
D000485:Allergens; D000706:Anaphylatoxins; C508717:IL17A protein, human; D020381:Interleukin-17; D015926:Complement C3a; D015936:Complement C5a
C3a; IL-17A; Seasonal allergic rhinitis; Sublingual immunotherapy